Ospedale Galeazzi S.p.A.
- Address
- lock Available on a paid plan
Cardiovascular Diseases
The Division of University Cardiology at Ospedale Galeazzi S.p.A. is advancing research on heart‑related conditions by testing innovative therapies aimed at reducing plaque buildup and valve calcification.
- Evaluation of inclisiran added to statin therapy to lower coronary atheroma volume.
- Assessment of pelacarsen for slowing progression of calcific aortic valve stenosis.
- Investigation of olpasiran on non‑calcified plaque volume using coronary CT angiography.
- Study of SGLT2 inhibitors to stabilize coronary atherosclerosis after acute myocardial infarction.
These trials reflect the hospital’s commitment to improving cardiovascular outcomes for patients across Europe.
Hemic and Lymphatic Diseases
Research at the site includes strategies to prevent blood‑clot related complications, particularly after orthopedic surgery, aiming to enhance safety for at‑risk individuals.
- Comparison of IV REGN7508 versus aspirin for preventing symptomatic venous thromboembolism after total knee arthroplasty.
- Evaluation of clot‑related biomarkers in patients with a history of venous thromboembolism.
- Long‑term safety monitoring of anticoagulant regimens in post‑surgical populations.
The work supports Ospedale Galeazzi S.p.A.’s role in reducing thrombotic risk for surgical patients.
Immune System Diseases
The cardiology division collaborates on studies targeting autoimmune conditions, focusing on symptom relief and disease‑modifying effects of novel agents.
- Effect of HZN-1116 on systemic manifestations and patient‑reported symptoms of Sjögren’s Syndrome.
- Long‑term safety and tolerability of subcutaneous secukinumab in polymyalgia rheumatica.
- Impact of Baricitinib on synovial inflammation in calcium pyrophosphate deposition disease.
These investigations aim to broaden therapeutic options for patients with challenging immune‑mediated disorders.
Musculoskeletal Diseases
A variety of trials address joint degeneration and chronic pain, testing regenerative approaches and analgesic medications to improve mobility and quality of life.
- Implantation of tissue‑engineered nasal cartilage (N‑TEC) versus standard care for patellofemoral osteoarthritis.
- Analgesic efficacy of DFL24412 compared with ketoprofen lysine salt in chronic low back pain.
- Weight loss and pain reduction outcomes with NNC0487‑0111 in overweight adults with knee osteoarthritis.
- Evaluation of Baricitinib on synovial tissue inflammation in calcium pyrophosphate deposition disease.
The site’s multidisciplinary approach seeks to restore function for patients suffering from musculoskeletal ailments.
Nutritional and Metabolic Diseases
Studies at the hospital explore metabolic risk factors and bone health, linking obesity, diabetes, and osteoporosis with cardiovascular complications.
- Effect of SGLT2 inhibitors on coronary atherosclerosis progression after myocardial infarction in diabetic patients.
- Comparison of Romosozumab versus denosumab on coronary atherosclerotic damage in post‑menopausal osteoporosis.
- Weight‑management and pain‑relief trial using NNC0487‑0111 for participants with excess body weight and knee osteoarthritis.
- Investigation of metabolic contributors to calcific aortic valve stenosis progression.
These efforts underline Ospedale Galeazzi S.p.A.’s dedication to integrating metabolic health with cardiovascular care.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 6 therapeutic areas and 15 of 31 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 8 by active trials.
- 1Ospedale Galeazzi S.p.A.2active
lock +7 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG7trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Ospedale Galeazzi S.p.A.
lock Showing 1 of 18 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Safety, Tolerability, and Effect of Olpasiran on Coronary Artery Plaque Burden Assessed by Coronary Computed Tomography Angiography in Participants With Stable Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a) | Amgen Inc. | Phase III | Recruiting | Mar 2026 | — |
IMP list
lock Showing 1 of 31 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Inclisiran | 3 | Unknown | 2022-08-16 | 2023-09-04 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.